Author

Renlei Ji

Harvard UniversityORCID 0000-0001-6258-1777Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Jean J. ZhaoiD· 3 shared Changli Qian· 2 shared Jing NiiD· 2 shared Anwaruddin MohammadiD· 1 shared Bose S. KochupurakkaliD· 1 shared Elena V. IvanovaiD· 1 shared Erica M. HoldridgeiD· 1 shared Geoffrey Ira ShapiroiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Jean J. ZhaoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyNature CommunicationsPeer-reviewedMay 4, 2026

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

Xin Cheng, Y Zhang, Changli Qian…·Jean J. Zhao

This study identifies FGFR signaling as a driver of resistance and immune evasion in PIK3CA-driven serous-like endometrial cancer and shows that dual FGFR/PI3K inhibition improves tumor control.

DOI 10.1038/s41467-026-72544-z

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 25, 2026

Targeting PI3Kβ-dependent cancer with a novel small molecule inhibitor, GT220

Qi Wang, Huimin Cheng, Xiangyang Yu…·Jean J. Zhao

This paper develops GT220, a selective PI3Kβ inhibitor, showing efficacy in PTEN-deficient cancers while sparing normal cells.

DOI 10.64898/2026.01.16.699992

humandeep learning

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 14, 2025

IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer

Yabing Nan, Sophie O'Keefe, Xiadi He…·Jean J. Zhao

This study identifies the IRG1/itaconate/NRF2/GSH axis in TAMs as a driver of PARPi resistance and immune evasion in BRCA1-deficient breast cancer, with pharmacological inhibition showing therapeutic potential.

DOI 10.1101/2025.10.14.682312

mouseproteomics

𝕏 PostBluesky